Closing the serological gap: Promising novel biomarkers for the early diagnosis of rheumatoid arthritis

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 318-322

  Trouw, Leendert A ^a   Mahler, Michael ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

Autoantibodies; CCP; Citrullinated cyclic peptide; RA; Rheumatoid arthritis

Indexed keywords

ALPHA ENOLASE; AMINO ACID; ANNEXIN; ANTIPERINUCLEAR FACTOR; B RAF KINASE; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FIBRINOGEN; FIBRONECTIN; FILAGGRIN; HOMOCITRULLINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; KERATIN ANTIBODY; RHEUMATOID FACTOR; VIMENTIN;

CARBAMOYLATION; DELAYED DIAGNOSIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SEROLOGY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; HUMANS;

EID: 84870237014     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.05.007     Document Type: Review

References (41)

1. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
2. van Venrooij W.J., van Beers J.J., Pruijn G.J. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011, 7:391-398.
3. Wiik A.S., van Venrooij W.J., Pruijn G.J. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 2010, 10:90-93.
4. Kokkonen H., Mullazehi M., Berglin E., Hallmans G., Wadell G., Ronnelid J., et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R13.
5. Willemze A., Trouw L.A., Toes R.E., Huizinga T.W. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012, 8:144-152.
6. Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
7. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
8. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
9. Kessenbrock K., Raijmakers R., Fritzler M.J., Mahler M. Synthetic peptides: the future of patient management in systemic rheumatic diseases?. Curr Med Chem 2007, 14:2831-2838.
10. Levesque M.C., Zhou Z., Moreland L.W. Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum 2009, 60:2211-2215.
11. Vander Cruyssen B., Nogueira L., Van Praet J., Deforce D., Elewaut D., Serre G., et al. Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis 2008, 67:542-546.
12. Bizzaro N., Tonutti E., Tozzoli R., Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007, 53:1527-1533.
13. Santiago M., Baron M., Miyachi K., Fritzler M.J., Abu-Hakima M., Leclercq S., et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008, 27:77-83.
14. Correia M.L., Carvalho S., Fortuna J., Pereira M.H. Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 2008, 34:21-25.
15. van der Linden M.P., van der Woude D., Ioan-Facsinay A., Levarht E.W., Stoeken-Rijsbergen G., Huizinga T.W., et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009, 60:2232-2241.
16. Jaskowski T.D., Hill H.R., Russo K.L., Lakos G., Szekanecz Z., Teodorescu M. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies. J Rheumatol 2010, 37:1582-1588.
17. van Venrooij W.J., Zendman A.J., Pruijn G.J. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006, 6:37-41.
18. Pruijn G.J., Wiik A., van Venrooij W.J. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010, 12:203.
19. Bossuyt X., Coenen D., Fieuws S., Verschueren P., Westhovens R., Blanckaert N. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis 2009, 68:287-289.
20. Willemze A., Bohringer S., Knevel R., Levarht E.W., Stoeken-Rijsbergen G., Houwing-Duistermaat J.J., et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 2012, 71:268-274.
21. Bartoloni E., Alunno A., Bistoni O., Bizzaro N., Migliorini P., Morozzi G., et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 2012, 11:815-820.
22. Pratesi F., Tommasi C., Anzilotti C., Puxeddu I., Sardano E., Di C.G., et al. Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. Clin Exp Immunol 2011, 164:337-345.
23. Dejaco C., Klotz W., Larcher H., Duftner C., Schirmer M., Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R119.
24. Soos L., Szekanecz Z., Szabo Z., Fekete A., Zeher M., Horvath I.F., et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007, 34:1658-1663.
25. Damjanovska L., Thabet M.M., Levarth E.W., Stoeken-Rijsbergen G., van der Voort E.I., Toes R.E., et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 2010, 69:730-732.
26. Nell V.P., Machold K.P., Stamm T.A., Eberl G., Heinzl H., Uffmann M., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005, 64:1731-1736.
27. Chandra P.E., Sokolove J., Hipp B.G., Lindstrom T.M., Elder J.T., Reveille J.D., et al. Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R102.
28. Shoda H., Fujio K., Shibuya M., Okamura T., Sumitomo S., Okamoto A., et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 2011, 13:R191.
29. Iaccarino L., Ghirardello A., Canova M., Zen M., Bettio S., Nalotto L., et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev 2011, 10:553-558.
30. Schett G., Dumortier H., Hoefler E., Muller S., Steiner G. B cell epitopes of the heterogeneous nuclear ribonucleoprotein A2: identification of a new specific antibody marker for active lupus disease. Ann Rheum Dis 2009, 68:729-735.
31. Somers K., Geusens P., Elewaut D., De K.F., Rummens J.L., Coenen M., et al. Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun 2011, 36:33-46.
32. Shi J., Knevel R., Suwannalai P., van der Linden M.P., Janssen G.M., van Veelen P.A., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011, 108:17372-17377.
33. Auger I., Charpin C., Balandraud N., Martin M., Roudier J. Autoantibodies to PAD4 and BRAF in rheumatoid arthritis. Autoimmun Rev 2012, 11:801-803.
34. Auger I., Martin M., Balandraud N., Roudier J. Rheumatoid arthritis-specific autoantibodies to peptidyl arginine deiminase type 4 inhibit citrullination of fibrinogen. Arthritis Rheum 2010, 62:126-131.
35. Auger I., Balandraud N., Rak J., Lambert N., Martin M., Roudier J. New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis 2009, 68:591-594.
36. Charpin C., Martin M., Balandraud N., Roudier J., Auger I. Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis. Arthritis Res Ther 2010, 12:R194.
37. Turunen S., Koivula M.K., Risteli L., Risteli J. Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits. Arthritis Rheum 2010, 62:3345-3352.
38. Bang H., Egerer K., Kraemer A., Burmester G.R. Carbamoylation of vimentin in patients with rheumatoid arthritis: identification of a novel protein modification with a possible link to disease pathogenesis. Arthritis Rheum 2012, 63:685.
39. Scinocca M., Bell D.A., Pope J., Cairns E., Barra L. Rheumatoid arthritis patients have anti-homocitrullinated fibrinogen antibodies. Arthritis Rheum 2012, 63:850.
40. dos Anjos L.M., Pereira I.A., 'Orsi E., Seaman A.P., Burlingame R.W., Morato E.F. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 2009, 28:153-158.
41. Conrad K., Roggenbuck D., Reinhold D., Dorner T. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev 2010, 9:431-435.